Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Lydia Gaba García

12PUBLICATIONS
114CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedMolecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

Sort by Publication Date:
|Jul 06, 2026
Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care.

|Dec 03, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Philipp Harter, Frederik Marmé, Andrés Redondo

|Jul 29, 2025
PET/CT Volumetric Parameters as Predictors of the Peritoneal Cancer Index in Advanced Ovarian Cancer Patients.

Ariel Glickman, Blanca Gil-Ibáñez, Aida Niñerola-Baizán

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

|Apr 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.

Joyce F Liu, Nicoletta Colombo, Amit M Oza

|Mar 11, 2025
Evaluation of chemotherapy-induced nausea and vomiting in low, moderate, and highly emetogenic schemes between sexes.

Marta Albanell-Fernández, Ma Carmen Rodríguez Mues, Carolina Figueras

Pageof 2

Frequent Collaborators

3 joint publications

Maria-Pilar Barretina-Ginesta

3 joint publications

Ana Oaknin

3 joint publications

Antonio González-Martín

3 joint publications

Nicoletta Colombo

3 joint publications

Florian Heitz

2 joint publications

María Jesús Rubio

2 joint publications

Zaida Garcia-Casado

2 joint publications

Margarita Romeo

2 joint publications

Ana Beatriz Sanchez-Heras

2 joint publications

Luisa Sanchez-Lorenzo

Frequent Collaborators

3 joint publications

Maria-Pilar Barretina-Ginesta

3 joint publications

Ana Oaknin

3 joint publications

Antonio González-Martín

3 joint publications

Nicoletta Colombo